© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 21st 2021, 1:30pm
While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.
April 18th 2021, 1:15pm
An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.
April 15th 2021, 1:45pm
New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).
April 13th 2021, 4:25pm
A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
April 6th 2021, 9:28pm
Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.
April 5th 2021, 6:46pm
Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.
April 1st 2021, 8:57pm
Idiopathic pulmonary arterial hypertension (PAH) is associated with iron deficiency, which is in turn associated with worse functional capacity and survival in PAH; however, iron repletion by infusion provided no significant clinical benefit.
March 27th 2021, 6:00pm
An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension.
March 21st 2021, 8:15pm
Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.
March 18th 2021, 1:15pm
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.